SCHEMBL886152

SCHEMBL886152

CCOC(=O)c1[nH]c(=O)n(-c2ccccc2)c1-c1ccccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAT2A P31153 1/20 0.48
MAPT P10636 5/20 0.47
ALDH1A1 P00352 5/20 0.47
GAA P10253 4/20 0.47
NPC1 O15118 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ALOX5 P09917 1/20 0.44
PKM P14618 1/20 0.44
MAPK1 P28482 1/20 0.44
RAB9A P51151 1/20 0.44
ATM Q13315 1/20 0.44
CHRNA7 P36544 1/20 0.44
HPGD P15428 3/20 0.43
KDM4E B2RXH2 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
RECQL P46063 1/20 0.41
GRM6 O15303 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TP53 P04637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL885461 0.84 MAT2A (0.53) MAT2AMAPTALDH1A1GAANPC1
SCHEMBL885925 0.84 GABRA2 (0.50) MAT2AMAPTALDH1A1GAANPC1
SCHEMBL885816 0.82 KMT2A (0.46) ALDH1A1GAAHPGDKDM4ENPSR1
SCHEMBL885431 0.82 GABRA2 (0.52) MAT2AMAPTALDH1A1GAANPC1
SCHEMBL6208469 0.80 MAPT (0.56) MAT2AMAPTALDH1A1GAANPC1
SCHEMBL885498 0.77 MAT2A (0.49) MAT2AMAPTALDH1A1GAANPC1
SCHEMBL885974 0.77 LMNA (0.40) ALDH1A1GAANPC1SMN1; SMN2ALOX5
SCHEMBL2063135 0.76 RXFP1 (0.49) ALDH1A1GAAHPGDHSD17B10LMNA
SCHEMBL16935808 0.76 ALDH1A1 (0.55) MAT2AMAPTALDH1A1GAANPC1
SCHEMBL8171508 0.76 MAT2A (0.52) MAT2AMAPTALDH1A1GAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089005-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 WO claimed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
WO-2008089005-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105665-A1 RENIN INHIBITORS REN, ACE, AGT MAT2A 2878/4885MAPT 2847/4885ALDH1A1 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.